No 4 (20): 5.

Clinical Medicine

 2020

Scientific article
pdf-version

Anna Anisimova
Petrozavodsk State University
(Petrozavodsk, Russian Federation),
tiny_d0ll@mail.ru

The features of diagnosis and clinical course of non-alcoholic steatohepatites

Scientific adviser:
Dudanova Olga Petrovna
Paper submitted on: 12/14/2020;
Accepted on: 12/23/2020;
 Abstract. Nowadays there is a great amount of undiagnosed cases of non-alcoholic fatty liver disease (NAFLD) due to lack of clean subjective and objective symptoms. At the same time, non-alcoholic steatohepatitis (NASH), the most progressive form of NAFLD, can cause the development of liver cirrhosis and hepatocellular carcinoma. This article examines the clinical status of NASH, traditional laboratory methods, which are used to recognize the liver damage degree, and fibrosis scales, NAFLD fibrosis score and FIB-4, which are limiting biopsy. Actually the clinic status of NASH is still oligosymptomatic and the main objective symptom is moderate increase in liver size and changes of echo-structure. The most informative laboratory indicators are alanin aminotransferase, cytokeratin – 18 fragments, tumor necrosis factor – alpha and triglycerides. It is important to note that NAFLD fibrosis score is proved to be the most informative in assessing liver fibrosis degree.
Keywords: non-alcoholic steatohepatites, alaninaminotransferase (ALT), cytokeratin – 18 fragments (CKF-18), tumor necrosis factor –alpha (TNF-a), liver fibrosis

For citation: Anisimova, A. The features of diagnosis and clinical course of non-alcoholic steatohepatites. StudArctic forum. 2020, 4 (20): 5.

References

1. Ivashkin V.T., Mayevskaya M.V., Pavlov C.S., Tikhonov I.N., Shirokova Y.N., Buyeverov A.O., Drapkina O.M., ShulpekovaYu.O., Tsukanov V.V., Mammayev S.N., Mayev I.V., Palgova L.K. Diagnostics and treatment of non-alcoholic fatty liver disease: clinical guidelines of the Russian Scientific Liver Society and the Russian gastroenterological association. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2016;26(2):24-42.

2. Lazebnik L.B., Radchenko V.G., Golovanova E.V., Zvenigorodskaya L.A., Konev Yu.V., Seliverstov P.V., Sitkin S.I., Tkachenko E.I., Avaluyeva E.B., Aylamazyan E.K., Vlasov N.N., Grinevich V.B., Korniyenko E.A., Novikova V.P., Khoroshinina L.P., Zhestkova N.V., Oreshko L.S., Dudanova O.P., Dobritsa V.P., Tur’Yeva L.V., Tirikova O.V., Kozlova N.M., Yeliseyev S.M., Gumerov R.R., Ventsak E.V., Aleshina E.I., Gurova M.M., Goryacheva L.G. NONALCOHOLIC FATTY LIVER DISEASE: CLINIC, DIAGNOSTICS, TREATMENT (Recommendations for therapists, 2nd edition). Experimental and Clinical Gastroenterology. 2017;(2):22-37. (In Russ.)

3. Shipovskaya A.A., Kurbatova I.V., Dudanova O.P. The use of cytokeratin-18 fragments in diagnostics of non-alcohol fatty liver disease Klin. med. 2017; 95 (10): 923—927. DOI http://dx.doi.org/10.18821/0023-2149-2017-95-10-923-927

4. Piazzolla VA, Mangia A. Noninvasive Diagnosis of NAFLD and NASH. Cells. 2020 Apr 17;9(4):1005. doi: 10.3390/cells9041005. PMID: 32316690; PMCID: PMC7226476.

5. Younossi Z.M., Koenig A.B., Abdelatif D., Fazel Y., Henry L., Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73–84. doi: 10.1002/hep.28431.

Displays: 765; Downloads: 210;